Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on August 26, 2004

Stroke. 2004
Published online before print August 26, 2004, doi: 10.1161/01.STR.0000141937.80760.10
A more recent version of this article appeared on October 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/10/2326    most recent
01.STR.0000141937.80760.10v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aiyagari, V.
Right arrow Articles by Diringer, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aiyagari, V.
Right arrow Articles by Diringer, M. N.
Related Collections
Right arrow Thrombolysis
Right arrow Cerebrovascular disease/stroke
Right arrow Acute Cerebral Infarction

Submitted on June 23, 2004
Accepted on July 22, 2004

Hourly Blood Pressure Monitoring After Intravenous Tissue Plasminogen Activator for Ischemic Stroke: Does Everyone Need It?

Venkatesh Aiyagari MBBS, DM*; Arunodaya Gujjar MBBS, DM; Allyson R. Zazulia MD; and Michael N. Diringer MD

From the Department of Neurology (V.A., A.R.Z., M.N.D.), Washington University School of Medicine, St. Louis, Mo; and the National Institute of Mental Health and Neurological Sciences (A.G.), Bangalore, India.

* To whom correspondence should be addressed. E-mail: aiyagariv{at}neuro.wustl.edu.

Background and Purpose--Blood pressure (BP) control is considered essential in patients treated with tissue plasminogen activator (tPA) for ischemic stroke, and it is recommended that BP be monitored every 15 minutes to 1 hour for 24 hours in these patients. We postulated that patients whose BP is not initially elevated are unlikely to have elevated BP later and, therefore, may not need prolonged BP monitoring.

Methods--We performed a retrospective chart review of patients treated with intravenous tPA for ischemic stroke over a 3-year period. Patients with incomplete records were excluded.

Results--Seventy-nine patients (35 male, age 68.8±14.3 years) were studied. Before tPA treatment, 16 patients (20%) had hypertension (systolic BP ≥185 or diastolic BP ≥110 mm Hg). All 16 patients had subsequent hypertension over the next 24 hours. Of the remaining 63, 27 patients (43%) had hypertension (systolic BP ≥180 or diastolic BP ≥105 mm Hg) within the first 6 hours. An additional 4 had minor transient systolic elevations (≤182 mm Hg) after 6 hours that normalized without treatment. Neurological worsening, seen in 13 patients (17%), was not associated with the presence of hypertension (initial or subsequent).

Conclusions--In patients receiving tPA for stroke, absence of hypertension at presentation does not preclude subsequent increase in blood pressure. However, if blood pressure is not elevated during the first 6 hours, subsequent hypertension over the next 18 hours is unlikely. This study is small and retrospective, and needs to be repeated in a larger prospective cohort. However, our results provide preliminary evidence to suggest that where resources are scarce, these patients may be discharged from the intensive care unit earlier than the recommended 24 hours, provided that they are not at high risk for neurological deterioration.


Key words: blood pressure • stroke • stroke units • tissue plasminogen activator




This article has been cited by other articles:


Home page
CirculationHome page
A. I. Qureshi
Acute Hypertensive Response in Patients With Stroke: Pathophysiology and Management
Circulation, July 8, 2008; 118(2): 176 - 187.
[Full Text] [PDF]